Stocks To Buy Now Blog

Stocks on Radar

Celldex Therapeutics, Inc. (CLDX) is “One to Watch”

Last month, Celldex Therapeutics, Inc. (NASDAQ: CLDX), a company in the business of developing targeted therapeutics for those suffering from devastating diseases for which current treatments are inadequate, found positive results from its phase II study of glembatumumab vedotin in patients with stage III/IV checkpoint inhibitor-refractory. The study showed that patients experienced a confirmed response, with 52% of patients experiencing tumor shrinkage. In addition, by close of market on November 8, 2016, Celldex stock was up significantly as investors reacted to the company’s third quarter earnings report, which surpassed estimates for revenue and EPS. CLDX’s stock rose by nearly 15% to close at $3.78 on 9.01 million shares, more than four times the company’s average.

Aside from its recent growth, Celldex announced the acquisition of Kolltan Pharmaceuticals, Inc. on November 1. Kolltan is a privately owned clinical-stage company that develops new antibody-based drugs and is worth $62.5 million in stock. “Celldex believes Kolltan’s clinical candidates and preclinical platform are highly compatible with the Company’s scientific approach and can be developed independently and in combination with Celldex’s existing product candidates,” according to a statement shared on the Scibility Media website (http://dtn.fm/aD3xZ).

On November 7, Aegis Capital Corp. (http://dtn.fm/bXxJ5) initiated coverage on Celldex Therapeutics, Inc., giving the company a ‘Buy’ rating and a target price of $10. In addition, as of November 8, 2016, ClosingBell Active Analyst Ratings (http://dtn.fm/0W6w6) gave CLDX an average stock rating of 3.6 on a one to five scale, with five denoting ‘Buy’ and one indicating ‘Sell’. The numbers above are predicted to allow Celldex Therapeutics, Inc. to fund its operations through 2018.

For more information, visit the company’s website at www.celldex.com

Neuralstem, Inc. (CUR) May Lift the Blues with its Novel Neurogenetic NSI-189

Major Depressive Disorder (MDD) afflicts about 15 million Americans and is the leading cause of disability in the U.S. for those aged 15-44, according to the National Institute of Mental Health. Although experiencing the blues is part of the human condition, MDD is more than just the sadness that accompanies misfortune. MDD is a chronic feeling of enervation, loss of interest in activities, pessimism and hopelessness. At one time regarded as caused by supernatural forces, today, modern medical science generally attributes depression to chemical imbalances in the brain. However, with its small-molecule benzylpiperazine-aminopyridine drug NSI-189, Neuralstem, Inc. (NASDAQ: CUR) has evolved a new approach to lifting the blues.

NSI-189 was developed as a result of the research, undertaken by Neuralstem, into neural stem cell lines from the human hippocampus. The hippocampus is a part of the brain involved in memory and the generation of new neurons. In a process referred to as neurogenesis, NSI-189 was shown to stimulate the generation of new neurons in vitro and in animal models. In phase Ib human clinical trials for MDD, NSI-189 demonstrated ‘clinically meaningful’ improvement across all depressive and cognitive measures.

This approach based on neurogenesis is a novel one. Current medications for depression generally attempt to modulate levels of different chemicals (neurotransmitters) in the brain. The most common type of such treatments is thought to be selective serotonin reuptake inhibitors (SSRIs).

In addition to the brain chemistry factors that cause depression, modern scholarship has uncovered a link between depression and the physiology of the brain. Those who suffer from chronic depression display reduced hippocampal volume. The healthy hippocampus, however, is a rich source of neural stem cells, from which new neurons are generated, making vital new connections throughout life. Neuralstem believes that stimulating the generation of new neurons in the hippocampus could potentially address the pathology of the depression itself.

Phase Ia trials, testing NSI-189 for use against MDD, kicked off in February 2011 and ended in October 2011. Healthy volunteers, unafflicted by depression, were tested with escalating single administration doses of NSI-189. Later, a similar trial was conducted for depression patients. In phase Ib, which commenced in June 2012 and ended in the fourth quarter of 2013, the safety of escalating doses of NSI-189 for 28 daily administrations in 24 patients suffering from MDD was tested.

At present, enrollment for a phase II trial has commenced. The trial, which is already 50 percent enrolled, is expected to yield top line results in the second half of 2017.

NSI-189 has had a colorful history. This feature in Bethesda magazine (http://dtn.fm/aRw8k) claims that NSI-189 stems from efforts by the Defense Advanced Research Projects Agency (DARPA), most famously home to the genesis of the internet, to cultivate ‘a “super soldier” who could stay awake and alert for a week at a time’. The contract was later cancelled and Neuralstem turned its attention to developing a remedy for the cell damage that can occur in the sleep-deprived hippocampus.

Neuralstem has the resources to expedite the clinical trial process. Through a recent agreement with the Tianjin Pharmaceutical Holding Group, the company has secured $20 million for completion of the phase II trial. This supplements the $11.1 million in cash on the balance sheet at the end of 2Q16.

In a report by Aegis Capital Corp. (http://dtn.fm/cZW0X), Neuralstem stock has been given a price target of $2.25. The share price on November 7 was $0.23. It seems that NSI-189 is lifting more than the blues.

For more information, visit www.neuralstem.com

Medical Transcription Billing, Corp. (MTBC) Announces Third Quarter Results

Before the opening bell, Medical Transcription Billing, Corp. (NASDAQ: MTBC; MTBCP) announced its financial and operational results for the third quarter of 2016, including a review of the October acquisition of MediGain, LLC and subsidiary Millennium Practice Management, LLC, which was the company’s largest acquisition to date. Notably, MTBC’s revenues for the three-month period were $5.3 million, up from $5.2 million in the previous quarter. The company also achieved its fourth consecutive quarter of positive adjusted EBITDA, reporting $130,000 for the third quarter and $209,000 year-to-date.

“We are pleased to announce another quarter of quarter-over-quarter revenue growth,” Mahmud Haq, chairman and chief executive officer of MTBC, stated in this morning’s news release. “Even though we continue to report a GAAP net loss, which is largely a result of non-cash amortization and depreciation expense, we are proud to report four consecutive quarters of positive adjusted EBITDA.”

Perhaps MTBC’s most significant achievement in the third quarter, the acquisition of Texas-based medical billing company MediGain, LLC, including substantially all of its assets and its subsidiary, positioned the company to build on its recent financial momentum moving forward. In total, the accounts in good standing acquired through this transaction have annual revenues in excess of $10 million. At a purchase price of just $7 million, the MediGain acquisition is expected to be accretive to MTBC shareholders in 2017, as incremental profits are expected to greatly exceed cost of capital. The acquisition also expanded MTBC’s global workforce, adding experienced team members in North America, as well as talented, cost-effective workforces in Asia.

“The successful closing of this transaction has positioned MTBC to experience exponential growth through access to new, untapped markets,” Haq continued. “In turn, we expect to expand our client base and deliver significant revenue growth in 2017.”

MTBC also reiterated plans for an upcoming offering of additional shares of its non-convertible Series A Preferred Stock in this morning’s update. The company is currently preparing to file a registration statement to sell 400,000 additional shares of its 11 percent Series A Cumulative Redeemable Perpetual Non-Convertible Preferred Stock at a price of $25 per share. If all of the shares are sold, the offering will generate roughly $9 million, of which $5 million will be used for the remaining payments related to the MediGain acquisition. This offering is not dilutive to shareholders and is expected to play a key role in positioning MTBC for forward growth.

Following this morning’s release, MTBC management hosted a conference call to discuss the results. An audio webcast of the call will be made available to the investment community on the company’s investor relations website at http://ir.mtbc.com.

For more information, visit www.mtbc.com, and see the company’s fact sheet at http://ir.mtbc.com/events.cfm.

Singlepoint, Inc. (SING) Set to Capitalize on Marijuana Industry Election Results

It is no secret that the United States is going through some serious changes when it comes to marijuana. In the recent election, several states approved the legalization of marijuana for recreational purposes, with other states voting to approve medical marijuana initiatives. With Donald Trump winning the presidential election, it brings forward the question: how will this new presidency affect the marijuana industry in the U.S.?

Prior to the election, Alicia Wallace from the Cannabist (http://dtn.fm/8zKZ3) was able to share the four leading presidential candidates’ views on marijuana, including Trump’s. While the leading third-party candidates supported the legalization of marijuana, the Democratic and Republican party candidates did not seem as convinced, although neither took a particularly strong public stance on the matter.

While Trump showed strong views in favor of the legalization of all drugs back in 1990, they have been modified. In his more recent interview, Trump backed the use of medical marijuana, though he believes recreational use should be up to the states.

Although there has been talk of New Jersey Governor Chris Christie, who is not in favor of the legalization of marijuana, being a contender for the post of Attorney General, the marijuana industry does not yet seem to be worried. During an interview with television reporter Brandon Rittiman, Trump stood by his view of it being ‘up to the states’.

As a result, Singlepoint, Inc. (OTC: SING) subsidiary SingleSeed, a cannabis focused company established a few years ago to offer payment processing services to dispensaries, aims to capitalize on its current status within the marijuana industry while expanding to additional states.

By the end of this year, the size of the legal marijuana industry in the U.S. is projected to grow to $7.1 billion, according to a report by New Frontier and ArcView Market Research (http://dtn.fm/vE0s3). This represents a 26% jump from 2015, which is said to be largely due to expected adult recreational sales. States which have legalized marijuana are seeing a growth in what people are calling “green” taxes. Colorado is a prime example of how the legalization of marijuana can contribute to the financial status of each state, with revenue in “green” taxes of $70 million between 2014 and 2015.

For more information, visit the company’s website at www.Singlepoint.com

Let us hear your thoughts: Singlepoint, Inc. Message Board

Alder Biopharmaceuticals, Inc. (ALDR) Promises to Relieve Migraine Misery with Leading Drug Candidate ALD403

A research report (http://dtn.fm/w6uT3) issued earlier this week by Aegis Capital Corp. shows that Alder Biopharmaceuticals, Inc. (NASDAQ: ALDR) has lived up to its promise since 2004, when it received startup funding from the Army under the Small Business Technology Transfer (STTR) program. Since then the company has been working on the development of new production technologies for humanized antibodies. Now it is close to making the fruits of that research available for the treatment of migraine, inflammatory diseases and autoimmune diseases with its lead product candidate, ALD403. Results of ongoing clinical trials are quite promising.

Trials of ALD403 go by the acronym “Promise”, which stands for PRevention Of Migraine via Intravenous ALD403 Safety and Efficacy. These clinical trials are taking two paths: Promise 1 for the treatment of frequent episodic migraine (FEM) and Promise 2 for the treatment of chronic migraine (CM).

Phase I clinical trials of ALD403 kicked off in May 2012 for the treatment of migraine headaches. In March 2013, in what is now Promise 1, the first patients were dosed with ALD403 in phase II proof-of-concept clinical trials for the treatment of FEM. In October 2015, pivotal trials of ALD403 for FEM were commenced.

Following on from the initial studies on ALD403, phase IIb clinical trials were initiated in November 2014 for the treatment of CM (Promise 2). In March 2016, positive top line data was announced from the Promise 2 phase IIb study in patients with chronic migraine.

Now, Alder is moving ALD403 into phase III trials for both Promise 1 and Promise 2. For Promise 1, the pivotal trials are expected to report results in the first half of 2017, while results for Promise 2 should be ready about one year later, in the first half of 2018.

Migraine is a neurological disorder that is more prevalent than is commonly presumed. According to the Migraine Research Foundation (MRF), the condition affects about 38 million men, women and children, i.e. about 12 percent of the U.S. population. Worldwide, the illness is the third most prevalent and affects some one billion people. The condition is characterized by intense or throbbing pain in the head, commonly accompanied by nausea, vomiting and high sensitivity to light and sound. Over time, patients may be subject to an increasing frequency and severity of migraine attacks, potentially leading to significant disability. The MRF estimates that U.S. employers lose more than $13 billion each year as a result of 113 million lost work days due to migraine.

Currently approved medications for migraine include beta blockers (such as propranolol), topiramate, sodium valproate and botulinum toxin, or Botox. These generally lead to a range of side effects, including cognitive impairment, nausea, fatigue and sleep disturbance. As a result, only about 12 percent of adults with frequent episodic or chronic migraine take preventive medications, according to the U.S. Agency for Healthcare Research and Quality reports. Alder believes this creates a significant unmet medical need for new treatments with improved safety and efficacy that can either prevent migraines completely or reduce the frequency to a level where patients can find adequate relief from existing abortive medications.

For more information, visit www.alderbio.com

eXp World Holdings (EXPI) Brokerage Passes 2,000-Agent Mark as More Members Join Every Day

Likely the fastest growing cloud-based brokerage in the United States, eXp Realty recently announced that it has passed the 2,000-agent mark as more and more real estate professionals are choosing to join its ranks every day. A subsidiary of eXp World Holdings, Inc. (OTCQB: EXPI), eXp Realty announced that it expanded its agent base to more than 2,000 members in a Twitter post a few days ago.

The Agent-Owned Cloud Brokerage™ reported having a total of 2014 agents at the end of October, and since then, dozens of new members have joined. This makes it very likely that the company will reach and even surpass its target of having 2,200 agents by the end of the year. In addition to the individual real estate agents that joined the brokerage over the last few days, several realty firms have also entered its ranks. The most recent addition is Arkansas’s number two realty firm, Burch & Co. Real Estate, which transitioned its entire team of 17 brokers and agents to eXp Realty. Before them, the Agent-Owned Cloud Brokerage™ was joined by leading Baton Rouge, Louisiana, firm Darren James Real Estate Experts; one of the top realty teams in California – Sacramento’s Brent Gove Team; and South Texas’s top international luxury agent, Miguel Herrera.

This accelerated growth is largely due to the business model proposed by eXp Realty, a model that has been continuously pushing the brokerage further and acted as the driving force behind its continued growth and that of its parent company, EXPI. eXp Realty is, first of all, a brokerage of the future, embracing the latest technologies and virtual and augmented reality advancements to create a tight-knit community of real estate professionals covering 41 states, the District of Columbia and Alberta, Canada. Its use of virtual reality and cloud-based platforms reflects a growing trend in the real estate market that’s expected to reach new heights in 2017, according to the annual PwC report ‘Emerging Trends in Real Estate®’ (http://dtn.fm/dsuI9). The analysis puts emphasis on the increased quality of service that augmented reality can bring and notes that experts expect up to $2.6 billion in real estate VR/AR applications by 2025.

As a fully cloud-based brokerage, eXp Realty conducts all its operations through a virtual reality platform, from agent training to lead generation, leadership meetings, exchanges of ideas and experience, IT services and many more. In addition to helping agents and brokers stay connected 24/7 from the comfort of their own homes, this model also eliminates all the expenses traditionally associated with owning and running a brick-and-mortar office, so brokerage members are able to provide more efficient services to their consumers and increase their own profit without spending too much out of pocket. Another attractive feature of the eXp Realty model is that it gives its members the opportunity to become owners through lucrative revenue sharing programs and by enabling them to become shareholders in exchange for their contributions to the company’s growth and development.

For more information, visit the company’s website at www.eXpWorldHoldings.com

Let us hear your thoughts: eXp World Holdings, Inc. Message Board

National Waste Management Holdings, Inc. (NWMH) Supporting Florida’s Recycling Efforts

Since 2008, Florida has been focusing its efforts on its new statewide recycling goal of 75%, to be achieved by 2020. This was later followed by an amendment in legislation to promote the production of renewable energy from waste. As a result of these changes, and others, the recycling rate in the state increased by 4% between 2012 and 2013, according to Waste Management World (http://dtn.fm/lw3BV).

These new efforts to increase Florida’s recycling rates found Jorge Caspary, director of the Division of Waste Management, urging organizations to increase their recycling efforts, since commercial municipal waste makes up approximately 55% of the total municipal solid waste in the state. Since the rise in recycling rate, the amount of solid waste has also increased, from just under 28 million tons to over 30 million, a large portion of this due to construction and demolition waste.

With this in mind, Florida’s Department of Environmental Protection (DEP) found that only about half of commercial solid waste in the state is being recycled. The department believes more commercial recycling would help the state reach its goal of a 75% recycling rate. Other organizations have the same vision and have joined the effort for a more sustainable Florida.

National Waste Management Holdings, Inc. (OTC: NWMH) is a solid waste management company located in Central Florida. The company provides solutions for full waste diversion, which include landfill, transfer stations, roll-off, mulch, and recycling services. More specifically, NWMH provides a construction and demolition (C&D) landfill in Hernando, Florida, servicing Citrus, Hernando, and Marion counties.

NWMH owns a 54 acre landfill facility and has an average annual disposal of approximately 110,000 cubic yards of construction debris. With new housing construction in the U.S. up significantly in recent years, and with further increase on the horizon, National Waste Management Holdings, Inc. plans to acquire complementary businesses, expand its national presence, and increase the operational efficiency of its existing business, all while supporting Florida’s goal to reach a 75% recycling rate target.

For more information, visit the company’s website at www.nationalwastemgmt.com

Let us hear your thoughts: National Waste Management Holdings, Inc. Message Board

FTE Network (FTNW) – A Unique Opportunity for Explosive Growth

The expansion in data usage and communications has continued to inflate beyond all predictions, with networks rapidly being pushed far beyond originally anticipated requirements. The unparalleled growth is expected to continue as developing technologies challenge existing capabilities, creating an unprecedented demand for improved network infrastructures and associated services.

Florida-based FTE Networks (OTCQX: FTNW) has grown to become a leading global provider of network infrastructure solutions, designing, building, and supporting networking infrastructures for major companies and government organizations in the U.S. and Europe. The company’s telecommunications and technology focused client base faces increased calls for expanding network capacity to satisfy the demands of their own customers for high-volume high-quality content at all levels. FTE’s must-meet goal is to provide the best in fast and reliable voice, data, and digital content delivery, all while living within critical cost limits. The only way to do this is by understanding the whole picture, offering integrated services and technologies in a flexible way that covers all aspects of telecommunication operation, including:

  • Data Center Infrastructure
    • Infrastructure Design
    • Deployment
    • Testing And Commissioning
    • Rack, Stack, Power
    • Cold Aisle Containment And Efficiency Programs
    • Maintenance
    • Integration
    • MDU Design & Deploy
    • AC/DC Power Plants
  • Fiber Optics
    • Row And Network Engineering
    • Large Scale Deployment
    • PMO
    • FTTX Solutions
    • Underground/Aerial
    • Deployment
    • Splicing & Testing
    • Fiber Characterization
    • Emergency Restoration
    • Maintenance
  • Wireless Integration
    • Engineering
    • Deployment
    • Maintenance
    • DAS Installations
    • RF Installations
    • Site Surveys, Acquisition & Zoning
    • Audits
    • Fiber Backhaul Solutions
    • Full Suite Of Testing
    • Solutions
    • Decommissioning
  • Surveillance & Security
    • Infrastructure Design
    • Deployment
    • Maintenance
    • Video Surveillance Design And Installation
    • Wi-Fi Installation
    • Storage Back-Up Solutions
    • Access Control

Through the leveraging of advanced technologies in creative ways, FTE has developed a remarkably flexible approach for addressing telecommunication challenges, providing a number of benefits to customers, as reflected in the company’s recent financial performance. FTE’s Q2 2016 financials show a 51% quarter over quarter revenue growth, along with improved margins. The company’s pipeline now totals approximately $166 million in annualized revenue, representing organic growth and a diversified customer base.

FTE Networks has just announced that SeeThruEquity, an independent equity research and corporate access firm, has initiated coverage on the company (available to members at www.SeeThruEquity.com/ftnw).

For additional information, visit the company site at www.FTENet.com, and its Investor Presentation at http://dtn.fm/Tg3oi.

Dominovas Energy Corporation (DNRG) Aims to Secure Natural Gas Supply in Johannesburg

Before the opening bell, Dominovas Energy Corporation (OTCQB: DNRG) announced that Michael Watkins, its chief operating officer and president of its fuel cell division, was recently dispatched to meet with a natural gas supplier in South Africa. Through this meeting, Dominovas Energy intends to secure a natural gas supply in order to facilitate the planned installation and operation of its RUBICON™ solid oxide fuel cell technology, including both the previously announced 50kW demonstration unit at the University of Johannesburg and additional commercial deployments currently in the company’s pipeline.

“My meetings were attended by key decision makers that highlighted their interest not only in expanding their distribution and sales of their product, but they also exhibited a true knowledge of and interest in the RUBICON’s ability to further expand consumer’s choices for electricity delivery,” Watkins stated in this morning’s news release. “The possible interaction between our companies would allow for an expanded market for them, as well as a profitable and sustainable market for the RUBICON™.”

The plan to secure a natural gas supply in South Africa comes after Dominovas Energy’s initial fuel solution of liquefied petroleum gas (LPG) was found to be problematic. LPG available in the region was found to be highly inconsistent in overall quality, and its transport created a number of logistical concerns that would hamper the viability of Dominovas Energy’s RUBICON™ technology moving forward. Using readily available natural gas as a fuel source, on the other hand, is expected to set a foundation for the company’s forward growth throughout Johannesburg and the surrounding region.

In addition to meeting with a natural gas supplier, Watkins visited with Dr. Tien Chien Jen, a professor with the University of Johannesburg’s Department of Mechanical Engineering, to further discuss the development of a research institute for the study of fuel cell systems at the University. Watkins also offered an update on the status of the ongoing natural gas supply discussions, which serve as a precursor to the highly-anticipated deployment of the 50kW RUBICON™ demonstration unit to the University of Johannesburg campus.

This morning’s announcement follows an update late last month that Dominovas Energy gave a successful presentation on the analysis of its Energy Solutions Survey to the University’s Central Technical Services Department. The survey, which aimed to identify the overall state of the institution’s energy usage, allowed Dominovas Energy to evaluate the ‘true’ cost of electricity and thermal generation on the campus while demonstrating the benefits that the RUBICON™ system could offer in terms of both capacity and efficiency.

For more information, visit www.DominovasEnergy.com

Let us hear your thoughts: Dominovas Energy Corp. Message Boards

Medical Transcription Billing, Corp. (MTBC) Goes HITECH with ChartScribe

Snuggled away under Title IV of the American Recovery and Reinvestment Act of 2009, Congress’ response to the Great Recession was the Health Information Technology for Economic and Clinical Health (HITECH) Act. Among other things, the HITECH Act provided incentives for providers of medical services to adopt electronic health records (EHR) through ‘Meaningful Use’ (MU). Although primarily aimed at stimulating economic activity and creating jobs, the framers of the law hoped that the application of information technology to the provision of medical services would improve healthcare. Medical Transcription Billing, Corp. (NASDAQ: MTBC) (NASDAQ: MTBCP), through its integrated digital transcription and patient charting services, is showing how that can be done.

MTBC’s charting services are designed to help physicians generate accurate, timely patient charts and better manage their time. Providers can conveniently send in digital audio dictations, and MTBC transcribes complete patient charts directly to their EHR portal. A patient chart is a complete record of a patient’s key clinical data and medical history that includes demographics, vital signs, diagnoses, medications, treatment plans, progress notes, problems, immunization dates, allergies, radiology images, and laboratory and test results. With MTBC’s charting services, doctors, physician assistants and other medical professionals can have their audio patient progress notes transcribed and the information entered into the appropriate EHR.

The integrated charting services are a core part of MTBC’s proprietary EHR, ChartsPro, the adoption of which will not only make delivery of service more efficient, but allow practitioners to reach ‘Meaningful use’ standards. ‘Meaningful Use’, under the HITECH Act, is the use of certified EHR technology, like ChartsPro, to improve the quality and safety of healthcare. MU sets objectives that providers must meet in order to qualify for the Medicare, Medicaid, Children’s Health Insurance, and Health Insurance Marketplace programs administered by the Centers for Medicare & Medicaid Services (CMS).

MU objectives were set to roll out in three stages. The first stage had an implementation deadline of year-end 2012 and involved procedures and technology to capture data and share it. It was expected that, by that time, 80 percent of patients would have records that employed a certified EHR technology. In August 2016, a survey conducted by Medscape (http://dtn.fm/YR1ua), a free online resource for physicians and health professionals, found that 91 percent were currently using an EHR system but that, at the end of 2012, just 74 percent were.

Stage two, with an implementation deadline of year-end 2014, had two core objectives. Firstly, eligible professionals were being encouraged to text patients by using ‘secure electronic messaging to communicate with patients on relevant health information’; and, secondly, hospitals must ‘automatically track medications from order to administration using assistive technologies in conjunction with an Electronic Medication Administration Record (eMAR)’.

MTBC’s digital transcription and patient charting services are fully compliant with MU standards, and a new menu set objective in MU stage two is included. This allows progress notes to be created, edited and signed by the practitioner. Objectives and measures for Stage three include increased thresholds, advanced use of health information exchange functionality, and an overall focus on continuous quality improvement.

Curating patient data is important to the advance of medical science, but a doctor burdened by data collection is one with less time for patients. With the overload of documentation and clerical responsibilities brought on by EHR, having an integrated charting service such as that offered by MTBC is essential.

For more information, visit www.mtbc.com, and see the company’s fact sheet at http://ir.mtbc.com/events.cfm.

From Our Blog

SuperCom Ltd. (NASDAQ: SPCB) CEO Presents Key Milestones and Strategic Initiatives at Investor Summit Virtual

September 17, 2025

SuperCom (NASDAQ: SPCB), a global provider of secured e-Government, IoT, and cybersecurity solutions, participated in the Q3 Investor Summit Virtual on September 16, 2025. President and CEO Ordan Trabelsi outlined the company’s recent milestones and strategic direction to an audience of small- and microcap investors (https://ibn.fm/3xi08). The Investor Summit is an exclusive virtual event for […]

Rotate your device 90° to view site.